Oliver Gassmann

Oliver Gassmann is a Full Professor of Technology Management with a focus on Innovation Management at the University of St. Gallen (HSG). He leads the Institute for Technology and Innovation Management (ITEM-HSG), specializing in research areas such as business model innovation, open innovation, pharmaceutical R&D efficiency, and digital sustainability. His work bridges strategic management and innovation ecosystems, emphasizing collaborative advantage in volatile markets.

**Education & Affiliations**: While formal educational details are not explicitly stated, his position as a Full Professor implies advanced academic credentials in technology or business management. His primary affiliation is with ITEM-HSG, where he contributes to executive education programs and industry partnerships.

**Research Interests**: Gassmann’s research explores how organizations innovate in dynamic environments, particularly in pharmaceuticals, digital platforms, and sustainability. Key themes include R&D productivity, AI-driven innovation, open innovation frameworks, and the governance of innovation ecosystems. He advocates for collaborative strategies to address challenges like VUCA (Volatility, Uncertainty, Complexity, Ambiguity) in business and science.

**Publications Trends**: Recent work focuses on pharmaceutical R&D benchmarks, AI’s role in business models, and platform ecosystems. His 2025 studies analyze FDA approval trends and Web3 implications for trust in digital platforms. Earlier publications (2020–2024) address smart cities, patent management in VUCA contexts, and frugal innovation strategies.

**Advising & Grants**: Supervised notable students like Charlotte-Katharina Lekkas and Maximilian Böger. His grants and projects likely involve industry collaborations, though specific funding details are not provided here. He actively contributes to policy discussions on intellectual property and innovation policy.

**Labs & Teams**: Oversees ITEM-HSG’s research initiatives, including studies on innovation ecosystems and digital transformation. His team collaborates with pharmaceutical companies, tech firms, and public institutions to develop actionable frameworks for innovation management.